We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Palatin Technologies

News List

Palatin Announces First Patient Enrolled in Dry Eye Disease Trial with PL9643 americanpharmaceuticalreview
March 09, 2020
Palatin Technologies has enrolled the first patient in a Phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED).
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women biospace
March 27, 2018
NDA includes data from two successful Phase 3 trials in HSDD in premenopausal women in which bremelanotide met the pre-specified co-primary efficacy endpoints
Palatin Technologies Announces FDA Clearance of IND Application for PL-8177 for Ulcerative Colitis biospace
January 04, 2018
Palatin Technologies announced today that the U.S. Food and Drug Administration (FDA) may continue its subcutaneous injection of PL-8177 as a potential clinical study of patients with ulcerative colitis